nitrendipine has been researched along with Ischemic Attack, Transient in 4 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dowlatshahi, D | 1 |
| Hill, MD | 2 |
| Boulanger, JM | 1 |
| Strauss, MH | 1 |
| Verma, S | 1 |
| Owen, A | 1 |
3 trials available for nitrendipine and Ischemic Attack, Transient
| Article | Year |
|---|---|
Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Data Interpretation, S | 2006 |
MOSES raises questions.
Topics: Acrylates; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Data Interpretation, Stati | 2006 |
MOSES: superiority or noninferiority?
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2006 |
1 other study available for nitrendipine and Ischemic Attack, Transient
| Article | Year |
|---|---|
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2009 |